
## Analysis period: 2011-2015

|                 | Years from diagnosis | Alive at start | Observed<br>Survival | CI 95%        | Relative<br>Survival * | CI 95%         |
|-----------------|----------------------|----------------|----------------------|---------------|------------------------|----------------|
| Males           | 1 year               | 67             | 96.6%                | 87.0% - 99.1% | 97.7%                  | 88.0% - 100.2% |
|                 | 2 years              | 62             | 88.8%                | 76.6% - 94.8% | 90.8%                  | 78.4% - 96.9%  |
|                 | 3 years              | 46             | 86.6%                | 73.8% - 93.4% | 89.5%                  | 76.3% - 96.5%  |
|                 | 5 years              | 39             | 83.9%                | 70.1% - 91.7% | 88.1%                  | 73.6% - 96.3%  |
| Females         |                      |                |                      |               |                        |                |
|                 | 1 year               | 166            | 95.8%                | 90.8% - 98.1% | 96.2%                  | 91.2% - 98.5%  |
|                 | 2 years              | 171            | 95.1%                | 89.9% - 97.6% | 95.8%                  | 90.7% - 98.4%  |
|                 | 3 years              | 160            | 94.4%                | 89.1% - 97.2% | 95.6%                  | 90.2% - 98.4%  |
|                 | 5 years              | 151            | 94.4%                | 89.1% - 97.2% | 95.6%                  | 90.2% - 98.4%  |
| Males & Females | _                    |                | 22.22/               |               | 00.00/                 |                |
|                 | 1 year               | 233            | 96.0%                | 92.2% - 98.0% | 96.6%                  | 92.8% - 98.6%  |
|                 | 2 years              | 233            | 93.4%                | 88.9% - 96.1% | 94.6%                  | 90.0% - 97.3%  |
|                 | 3 years              | 206            | 92.4%                | 87.7% - 95.3% | 94.1%                  | 89.3% - 97.1%  |
|                 | 5 years              | 190            | 91.8%                | 87.0% - 94.9% | 94.1%^                 | 89.3% - 97.1%  |

## **Observed Survival**

## 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% Males 20.0% Females ----- Males & Females 10.0% 0.0% 2 3 1 Years from diagnosis

## Relative Survival \*



- \* Relative Survival probability was calculated as the ratio of the observed survival rate in the cancer patients under study to the expected survival rate in the general population with similar gender and age distribution (Ederer II method). Relative survival represents a proxi of the cancer-specific survival. The *period* approach was used to derive more up-to-date relative survival estimates (follow-up period window= 01.01.2011-31.12.2015).
- A For international comparison consider the 5-yr age-standardized relative survival probability rate (Corazziari I. et al., EJC 2004): (M&F) 90.1% (CI 95%: 85.0% 95.4%).



